Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery CoTx-101 represents a potential breakthrough for ...
Powered by Coave's first-in-class proprietary suprachoroidal vector (coAAV-SCS), CoTx-101 represents a potential breakthrough treatment for retinal vascular diseases, combining the three essential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback